New hope for lung cancer patients who stopped responding to treatment

NCT ID NCT07601048

First seen May 22, 2026 · Last updated May 22, 2026

Summary

This study tests a new drug called HRS-7058 in people with advanced or spreading non-small cell lung cancer that has a specific change in the KRAS gene (G12C). Participants must have already tried standard treatments without success. The study compares HRS-7058 to other KRAS G12C-targeting drugs to see which works better at slowing cancer growth and improving survival. About 450 adults aged 18 to 75 will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WHO HAVE FAILED STANDARD TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, 300060, China

    Contact

Conditions

Explore the condition pages connected to this study.